Home

MICHEL DE ROSEN

CIK 1187148 · Chief Executive Officer · last filed 2021-06-11

MICHEL DE ROSEN is a Chief Executive Officer who has filed 13 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for DBVT, was dated Jun 11, 2021. Across all open-market trades the lifetime net is −$3.6M, making them a net seller over the disclosed history. 5 SEC filings were submitted jointly with ENDO PHARMACEUTICALS HOLDINGS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

13

Lifetime Open-Market Net

-$3.55M

Filer Profile

Reported Address
C/O VIROPHARMA INC
405 EAGLEVIEW BLVD
EXTON, PA 19341
Related Filers
ENDO PHARMACEUTICALS HOLDINGS INC — 5 joint filings, latest 2008-07-01
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DBVT Director — $11.85 — $0 1 2021-06-11
VIROPHARMA INC (VPHM) Delisted Chief Executive Officer 144,847 — — -$3.55M 8 2008-11-12
ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted Director 5,315 $0.29 $1.6K $0 4 2008-07-01

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-06-11 DBVT Buy (P) — $0 EDGAR
2008-11-12 VIROPHARMA INC (VPHM) Delisted Sell (S) −300,677 -$3.65M EDGAR
2008-07-01 ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted Grant (A) +155 $0 EDGAR
2008-04-02 ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted Grant (A) +157 $0 EDGAR
2008-04-02 VIROPHARMA INC (VPHM) Delisted Grant (A) — $0 EDGAR
2008-03-14 ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted Grant (A) +2,741 $0 EDGAR
2008-02-15 VIROPHARMA INC (VPHM) Delisted Exer (M) +36,900 $100.0K EDGAR
2008-01-15 VIROPHARMA INC (VPHM) Delisted Grant (A) — $0 EDGAR
2007-09-06 VIROPHARMA INC (VPHM) Delisted Exer (M) +39,477 $100.0K EDGAR
2007-08-17 VIROPHARMA INC (VPHM) Delisted Buy (P) +12,120 $99.0K EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.